Current stage-Stage IV - Page 2 of 32 Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Evaluating the outcomes of patients with advanced melanoma with different treatments

Posted by on Dec 7, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out how well patients with advanced melanoma treated with certain medications survived outside of clinical trials. The study found that patients treated with nivolumab (Opdivo) and ipilimumab (Yervoy) or patients treated with anti-PD1 antibodies had longer survival compared to those treated with BRAF/MEK...

Read More

Vitamin D is associated with improved survival outcomes of patients with advanced colorectal cancer

Posted by on Nov 29, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the association between vitamin D blood levels and survival outcomes in patients with metastatic colorectal cancer (mCRC). Researchers suggested that higher levels of vitamin D in the blood were associated with better survival. Some background CRC is the third most common cancer in the US. Among CRC patients, only...

Read More

Can bisphosphonates improve treatment outcomes for patients with lung cancer spread to the bones?

Posted by on Nov 3, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated whether zoledronate (Zometa) combined with TKI therapy is more effective than TKI therapy alone for patients with non-small cell lung cancer (NSCLC) spread to the bones. This study concluded that adding zoledronate to TKI therapy improved survival outcomes for these patients. Some background NSCLC is the most common...

Read More

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for HER2+ advanced breast cancer

Posted by on Nov 2, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which treatment resulted in better overall survival for patients with HER2+ breast cancer; trastuzumab emtansine (Kadcycla) with or without pertuzumab (Perjeta), or trastuzumab (Herceptin) plus a taxane. The study found that the overall survival was similar across...

Read More

A later introduction of anti-EGFR drug is as effective as the standard therapy for advanced colorectal cancer

Posted by on Oct 27, 2019 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of chemotherapy combined with bevacizumab (Avastin) or anti-EGFR drugs for treating advanced colorectal cancer (CRC). Researchers suggested that anti-EGFR later introduced in the treatment of these patients did not impact the outcomes of patients.  Some background CRC is the third most common...

Read More

Regular physical activity is associated with improved outcomes for advanced colorectal cancer

Posted by on Oct 20, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of physical activity (PA) on the outcomes of patients with advanced colorectal cancer. Researchers suggested that regular PA is associated with better outcomes for these patients. Some background Colorectal cancer is the third most common cancer worldwide. A significant number of patients...

Read More

Should additional chemotherapy be added to chemoradiotherapy in patients with inoperable non-small cell lung cancer?

Posted by on Oct 20, 2019 in Lung cancer | 0 comments

In a nutshell This study examined how effective additional chemotherapy alongside chemo-radiotherapy is in patients with locally advanced non-small cell lung cancer. The study found that additional chemotherapy did not bring survival benefits in these patients. Some background Non-small cell lung cancer (NSCLC) can be difficult to treat. There are a...

Read More

Evaluating long-term outcomes of nivolumab plus ipilimumab for patients with advanced melanoma

Posted by on Oct 20, 2019 in Melanoma | 0 comments

In a nutshell This study compared nivolumab (Opdivo) plus ipilimumab (Yervoy) to either drug alone for the treatment of advanced melanoma. The authors concluded that nivolumab plus ipilimumab or nivolumab alone increased survival compared to ipilimumab alone for these patients. Some background Advanced melanoma is a type of skin cancer that...

Read More

Atezolizumab in non-squamous non-small cell lung cancer – is it effective when combined with chemotherapy?

Posted by on Oct 12, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated if atezolizumab (Tecentriq) combined with chemotherapy (CT) is effective in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC). They found that this treatment improved survival in these patients. Some background Non-small cell lung cancer (NSCLC) is the most common lung cancer...

Read More

Looking for patients with hormone-receptor positive metastatic breast cancer to test an experimental biological drug

Posted by on Sep 30, 2019 in Breast cancer | 0 comments

In a nutshell This study is examining the effectiveness of biological drug sacituzumab govitecan (IMMU-132) compared to standard treatments for patients with hormone receptor-positive metastatic breast cancer. The main outcomes that will be measured are cancer responsiveness to the drug and survival of patients without the cancer growing. This trial...

Read More